Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JPMorgan Chase & Co (JPM) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
JPMorgan Chase & CoTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs JPMorgan Chase & Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while JPMorgan Chase & Co trades at $366 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 32.5× Alnylam Pharmaceuticals, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYJPM
Market Cap
$29.60B$962.37B
Sector
HealthFinancials
52-Week High
$491.22$362.04
52-Week Low
$205.48$282.84
Enterprise Value
$27.56B
Volume
10,479,943
Dividend Yield
1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

JPMorgan Chase & Co

JPMorgan Chase & Co. (JPM) trades at $365.63, up 1.62% today, with a bullish technical outlook and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to an estimated $194.9B in 2026. The stock shows robust profitability with a net income margin of 33.38% and ROE of 18.43%, supported by a moderate P/E of 15.51. Analyst consensus is a 'Moderate Buy' with a $374.18 price target, indicating potential upside amid positive sentiment.

JPM offers a solid investment case driven by earnings growth and sector leadership, but faces risks from macroeconomic volatility and geopolitical tensions. The stock's current price near resistance at $366 requires monitoring for breakout potential, while institutional accumulation and CEO insights on economic risks highlight both opportunity and caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About JPMorgan Chase & Co

JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.

Read more on JPM